1. Generics Bulletin
  2. >>Business
  3. >>Manufacturing

The Factory Floor: Suanfarma Expands API Capacity With Sandoz Deal In Italy

Meanwhile, Glenmark, Aurobindo And Cipla Have Run-ins With The FDA.

 
• By Akriti Seth

Suanfarma acquires an API manufacturing facility in Italy to accelerate its growth in Europe, while CapsCanada relocates its headquarters as part of its growth strategy. Meanwhile, Glenmark, Aurobindo and Cipla struggle with quality issues.

Scientist_Lab
The latest growth initiatives and quality control measures in the pharma space • Source: Shutterstock

Suanfarma Group has struck a deal with Sandoz Industrial Products to acquire an active pharmaceutical ingredient manufacturing facility in Rovereto, Italy. With this new acquisition Suanfarma expects “to reach €300m ($330m) turnover by 2020.”

Héctor Ara, president of Suanfarma, said “we are impressed by the know-how at the Rovereto site and intend to leverage...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

More from Business

Stelara Biosimilar Sees Stada’s Specialty Sales Start Strong In Q1

 
• By Dave Wallace

Stada’s Specialty division was boosted by the firm’s launch last year of a European Stelara biosimilar, even as generics growth remained muted in Q1.

Corapharm Deal Offers South-East Europe Opportunity For mAbxience

 
• By Dave Wallace

Hot on the heels of a recent alliance in Italy, biosimilars developer mAbxience has struck another deal – this time partnering with Corapharm in south-east Europe.

Big In Japan: Samsung Bioepis Looks To Increase Presence With Nipro Partnership

 
• By Dean Rudge

Ahead of being spun out of its parent company Samsung Biologics later this year, Samsung Bioepis has struck an agreement to bolster its presence in another Asian market and one of the largest global pharma markets.